Focusing on children
Children are the most vulnerable to malaria.1 Every two minutes, a child dies from malaria in Africa.2
In 2009, Novartis launched the first ACT with a tailored formulation meeting the World Health Organization (WHO) requirements for a pediatric antimalarial medicine.
Since its launch, we have delivered more than 300 million treatments of our pediatric antimalarial without profit to more than 40 endemic countries. Never before have so many pediatric treatments been distributed in such a short time frame for children suffering from malaria.
“Novartis has done a tremendous job of bringing an innovative drug to the vulnerable young victims of malaria in Zambia and over 50 other countries, giving it global reach. We at MMV are proud to have partnered with Novartis on the development of this important formulation.”
David Reddy, CEO of Medicines for Malaria Venture
This treatment is the result of a public-private partnership between Novartis and Medicines for Malaria Venture, a nonprofit foundation dedicated to the development of affordable new antimalarials.
The sweet-tasting formulation dissolves quickly in small amounts of water, without the need for cutting or crushing tablets, which enhances its use in young children.3
The medicine contains the same amount of active ingredients as the regular tablet – but represents an attractive alternative for infants and children (weighing 5kg and more) who typically find it difficult to swallow crushed, bitter pills.
Professor Awa Marie Coll-Seck
“Thanks to initiatives like the Novartis Malaria Initiative, people can have hope. We will be able to really tackle this disease and one day maybe, for the next generation, there will be a malaria-free world.”
Professor Awa Marie Coll-Seck, Former Executive Director, Roll Back Malaria Partnership
In an effort to ease adherence to the therapy in areas where illiteracy is still high, we developed a special packaging with pictograph instructions.
The packaging strengthens the impact of the dialogue between the healthcare professional and the caregiver or patient. The pictograms illustrate the ‘how’, ‘what’ and ‘when’ of the treatment, and the ‘why’ is also explained: by depicting the diminishing parasite load, patients are motivated to complete the full course of the three-day therapy, even if they do feel better already after one or two days.
Novartis worked with a host of health partners to design this innovative packaging – which received the “Drug Packaging Design Award” from the Healthcare Compliance Packaging Council in 2009.
- WHO World Malaria Report 2015, pages x-xiv: http://www.who.int/malaria/publications/world-malaria-report-2015/report/en
- WHO Malaria Factsheet No.94, January 2016: http://www.who.int/mediacentre/factsheets/fs094/en
- WHO Guidelines for the treatment of malaria. Third edition (2015) Available at: http://www.who.int/malaria/publications/atoz/9789241549127/en